GermanyGermany

Stopping malaria at the membrane

08.07.2010

Hamburg – To survive in man, the malaria parasite Plasmodium falciparum needs to enter the red blood cells for reproduction. Researchers from the Bernhard ­Nocht Institute for Tropical Medicine in Hamburg have now identified the internal signal that triggers the invasion of human erythrocytes. “To enter the cell, the parasites first have to come into intimate contact with the blood cells,” says Tim Gillberger, who conducted the research (PLoS Pathog. 6(6):e1000941). “If we are able to block the molecular mechanism behind that process, the pathogen wouldn’t stand a chance of successful infection.“ Gillberger and colleagues have already started compound screening for so-called PfPKA inhibitors – compounds that block the enzyme cAMP dependent protein kinase A. As the researchers reported in mid-June, PfPKAs are required for the formation of so-called tight junctions between Plasmodium and the blood cell. The enzymes activate the parasite surface protein AMA1 by phosphorylation, which triggers formation of tight junction formation and thus blood cell invasion. Gilberger believes the discovery opens the path to the development of new malaria drugs and vaccines.



GermanyGermany

16.08.2011

Berlin – Despite intense marketing measures, revenues from Epigenomics’ Epi proColon bowel cancer test remain flat. Along with its QII/2011 numbers, the Berlin-based in vitro diagnostic specialist revealed strict cost-saving...

GermanyGermany

05.08.2011

Boehringer Ingelheim is the first around the post. The European Commission cleared the German company's oral anticoagulant Pradaxa (dabigatran etexilate) for preventing stroke in atrial fibrillation patients at risk of stroke....

GermanyGermany

27.07.2011

Berlin – Reprogramming fibroblasts into human induced pluripotent stem cells (hiPSCs) can cause mitochondrial diseases, according to two reseearch groups from Berlin-based Max Planck Institute for Molecular Genetics. In every...

Germany, UKGermany

21.07.2011

In a first for European drug research, scientists have launched a clinical trial of an anti-HIV biotech medicine produced using genetically modified tobacco. Transgenic tobacco plants are grown for 45 days before being processed...

Germany, SwitzerlandGermany

19.07.2011

Basel - Roche goes shopping in Germany. The Swiss pharmaceutical giant agreed to buy privately-held mtm laboratories, a specialist in diagnostics for detecting cervical cancer based in Heidelberg, for up to 190 million...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

Displaying results 31 to 40 out of 454

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/3/article/stopping-malaria-at-the-membrane.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products